Rapid Micro Biosystems stock trades 1.83 percent above yearly low

Rapid Micro Biosystems stock (ISIN US75340L1044) stood at USD 1.11 on Nasdaq on September 23, 2026, 1.83 percent above its 52-week low of USD 1.09. The company is scheduled to present at 10:45 a.m. ET on September 24, 2026, at the Sidoti Small-Cap Virtual Conference, according to GlobeNewswire.

Revenue reached USD 8.1 million

Rapid Micro Biosystems reported second-quarter 2026 total revenue of USD 8.1 million, an 11 percent increase from USD 7.3 million in the second quarter of 2025. The company also placed four Growth Direct systems and completed nine system validations during the quarter, according to the Rapid Micro Biosystems investor relations page.

The revenue mix offers the more important operating signal. Product revenue rose 10 percent to USD 5.3 million, while service revenue increased 13 percent to USD 2.8 million in Q2 2026, according to the Equibles earnings-call transcript.

200 systems mark commercial scale

Management said the quarter marked placement of the 200th Growth Direct system globally. Consumable revenue grew more than 20 percent year over year, and recurring revenue rose 14 percent, showing why installed-system expansion matters beyond the initial instrument sale.

Rapid Micro Biosystems uses the Growth Direct platform to automate microbial quality-control testing for pharmaceutical and other healthcare manufacturing. Its platform combines instruments, disposable components, software integration and validation services, giving recurring consumables and service revenue a direct link to customer utilization.

Stock sits above its yearly low

The September 23 quote of USD 1.11 was accompanied by a daily change of minus 2.63 percent on Nasdaq. The combination of a price 1.83 percent above the 52-week low and double-digit quarterly revenue growth leaves execution and recurring revenue conversion as the key measurable checkpoints for the stock.

More news and analyses on Rapid Micro Biosystems stock